Pharma Catches A Break As Democrats Stumble In Rollout Of Pricing Investigation
Executive Summary
House Oversight Committee plans to grill more companies on pricing later this year, but rushed rollout of reports from a long-running investigation, combined with competing higher profile news events, seemed to dampen the blow of the latest drug pricing scrutiny. Democrats failed to offer any new, unified solutions for their grievances with industry, while Republicans largely rushed to pharma’s defense.
You may also be interested in...
AbbVie’s Stalling Tactics On Humira Pay Off – In More Ways Than One
A US House hearing focused on long-standing criticism of AbbVie for its ability to delay biosimilar competition for Humira. AbbVie was also able to delay the hearing, and that also seemed to work out well for the company.
Democrats’ New Wave Leads Attack On Pharma At Drug Pricing Hearing
The last quarter of the four-hour hearing may be a warning of things to come for pharma if the newer guard of Democrats keeps gaining traction among voters and power in Congress.
US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches
Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.